GALAXY MEDICARE LIMITED

Plot No.-2, Zone-D, Phase-A, Mancheswar Industrial Estate
Bhubaneswar - 751 010, INDIA,
Tel. : +91-7064810000
E-mail : info@galaxy.in
Web : http://www.galaxy.in
CIN : U24232OR1992PLC003113
GSTIN : 21AAACD7880L1ZI

An ISO 9001:2015 CERTIFIED COMPANY
Reg. No. 99 100 11576

ISO 13485:2016

Date: 14th November 2026

To,
The Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai - 400051

NSE SYMBOL: GML	ISIN: INE09A801015

Sub: Outcome of Board Meeting as Per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In Terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We Wish to Inform You That a Meeting of the Board of Directors of the Company held on Saturday, 14th November, 2026, at 4.00 P.M and Concluded at 6.30 P.M., Wherein the Board Passed the Following Resolutions:

1. Considered, Approved and Taken on Record the Un Audited Financial Results of the Company for Half Year Ended on 30th September, 2026 along with the Limited Review Report.

2. Declaration in respect of Unmodified Opinion on Un Audited Financial Results (Standalone) for the Half Year Ended on 30th September, 2026, Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Taking Note of Statement of Deviation(s) or Variation(s) Under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

In accordance with the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window shall remain closed for Designated Persons till 48 Hours after the Declaration of the Un Audited Financial Results for the Half Year Ended on 30th September 2026.

You are requested to kindly take the above information on record.

Thanking You.

Yours Faithfully,

For Galaxy Medicare Limited

PRALAAJU NAIK

Digitally signed by PRALAAJU NAIK
DN: c=IN, o=Personal, title=66199, 2.5.4.20=7909a0cca0c8f6d76c81b1bf5e615d bd49f31e e61aa6bdcb1cffe159cb2d8aaee3 8, postalCode=751 015, st=Orissa, serialNumber=e5de9fa8bdaaa437 73796e93 1506ac78 f254a78 746577 89d4da2980ac5208c6 9f910de, cn=PRALAAJU NAIK
Date: 2026.11.14 18:42:43 +05'30'

Pralaaju Naik
(Company Secretary)

INDIA

A.K. SABAT & CO.
CHARTERED ACCOUNTANTS

Plot No. : A / 348, Saheed Nagar,
Bhubaneswar - 751007, Odisha
Phone : 0674-2548264, 2549383
E-mail : aksabatco@gmail.com

Limited Review Report on Unaudited Financial Results for half year ended 30th September, 2026 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

LIMITED REVIEW REPORT

To
The Board of Directors of
Galaxy Medicare Limited

We have reviewed the accompanying statement of Unaudited Financial Results ("the statement") of GALAXY MEDICARE LIMITED (the Company) for the half year ended 30th September, 2026 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

This Statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Accounting Standard prescribed under Section 133 of the Companies Act, 2013, read with Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Emphasis of Matter:

We draw attention to Note no 7 of the Financial Results, where the Company has paid ₹ 50 lakh as advance to the Book Running Lead Manager (BRLM) appointed for the IPO before receipt of IPO proceeds but the same has not been adjusted by the BRLM while recovering its IPO fees from Escrow Collection Account. The amount is shown as advance recoverable and shown under 'Short Term Loans and Advances'.

Our conclusion is not modified in respect of this matter.

A.K. SABAT & CO. Bhubaneswar Chartered Accountants

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bhubaneswar
Date: 14.11.2026

A.K. SABAT & CO. Bhubaneswar Chartered Accountants

For A K Sabat & Co
Chartered Accountants
FRN: 321012E

(CA B.R. MOHANTY)
Partner
Membership No: 057266
UDIN:26057266PIEJLP1416

GALAXY MEDICARE LIMITED

Regd. Off: Plot No-2,Zone-D,Phase-A, Mancheswar Industrial Estate,Bhubaneswar

CIN-U242320R1992PLC003113

www.galaxy.in, Email-info@galaxy.in

Balance Sheet as at 30th September, 2026

(Amount ₹ in Lakh)

	Particulars	As at 30th September, 2026 (Unaudited)		As at 31st March,2026 (Audited)	
I.	**EQUITY AND LIABILITIES**				
1	**Shareholders' Funds**				
	(a) Share Capital	1,517.20		1,517.20	
	(b) Reserves and Surplus	2,616.36		2,516.70	
			4,133.56		**4,033.90**
2	**Non-Current Liabilities**				
	(a) Long-Term Borrowings	48.02		48.69	
	(b) Deferred Tax Liabilities (Net)	33.49		21.49	
	(c) Other Long Term Liabilities	16.00		16.00	
	(d) Long-Term Provisions	28.76		28.76	
			126.27		**114.94**
3	**Current Liabilities**				
	(a) Short-Term Borrowings	350.23		371.42	
	(b) Trade Payables				
	(A) total outstanding dues of micro enterprises and small enterprises	235.77		176.62	
	(B) total outstanding dues of Creditors other than micro enterprises and small enterprises	143.40		72.01	
	(c) Other Current Liabilities	157.73		106.74	
	(d) Short-Term Provisions	1.71		1.71	
			888.84		**728.50**
	TOTAL		**5,148.67**		**4,877.34**
II.	**ASSETS**				
1	**Non-Current Assets**				
	(a) Property, Plant and Equipment and Intangible Assets				
	(i) Property, Plant and Equipment	1,499.83		1,503.24	
	(ii) Intangible Assets	-		-	
	(b) Non-Current Investments	277.12		277.12	
	(c) Other Non Current Assets	12.28		5.17	
			1,789.23		**1,785.53**
2	**Current Assets**				
	(a) Current Investments	9.83		9.89	
	(b) Inventories	847.36		562.06	
	(c) Trade Receivables	637.89		761.54	
	(d) Cash and Cash equivalents	1,376.67		1,321.69	
	(e) Short-Term Loans and Advances	165.23		215.86	
	(f) Other Current Assets	322.46		220.76	
			3,359.44		**3,091.81**
	TOTAL		**5,148.67**		**4,877.34**

For and behalf of Board of M/s Galaxy Medicare Limited

For Galaxy Medicare Ltd.

Managing Director

Dillip Kumar Das
Managing Director
DIN-00402931

Place: Bhubaneswar

Date : 14/11/2026

A.K. SABAT & CO. Bhubaneswar Chartered Accountants

GALAXY MEDICARE LIMITED

Regd. Off: Plot No-2,Zone-D,Phase-A, Mancheswar Industrial Estate,Bhubaneswar

CIN-U242320R1992PLC003113

Statement of Unaudited Financial Results for the half year Ended on 30th September,2026

(Amount₹ in Lakh)

	Particulars	For the Half Year ended 30th Sept,2026	For the Half Year ended 30th Sept,2025	For the Half Year ended 31st March,2026	For the Year ended 31st March,2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from Operations	2,018.91	1,873.17	2,127.16	4,000.33
II.	Other Income	104.65	33.30	97.90	131.20
III.	**Total Income (I + II)**	**2,123.56**	**1,906.47**	**2,225.06**	**4,131.53**
IV.	**EXPENDITURE :**				
	Cost of Materials Consumed	1,388.80	1,160.19	1,249.47	2,409.66
	Purchase of Trading of Goods	81.63	52.63	33.82	86.45
	Change in Inventories				
	Finished Goods	(9.22)	(23.82)	11.93	(11.89)
	Work-In-Progress	(102.04)	(65.13)	90.28	25.16
	Stock in Trade	(30.68)	(15.96)	16.41	0.45
	Employee Benefits Expenses	257.75	248.27	300.22	548.49
	Finance Costs	16.03	11.44	16.25	27.69
	Depreciation and Amortization expense	39.78	29.87	25.57	55.44
	Other Expenses	263.49	231.33	288.07	519.40
V.	Total Expenses	**1,905.53**	**1,628.82**	**2,032.03**	**3,660.85**
VI.	**Profit/(Loss) Before Exceptional and Extraordinary Items and Tax (III-IV)**	218.03	277.65	193.03	470.68
VII.	Exceptional Items	-	-	-	-
VIII.	**Profit/(Loss) Before Extraordinary Items and Tax (V - VI)**	218.03	277.65	193.03	470.68
IX.	Extraordinary Items	-	-	-	-
X	**Profit/(Loss) Before Tax (VII- VIII)**	218.03	277.65	211.42	470.68
	Tax Expenses:				
	(1) Current Tax	(53.30)	(71.63)	(43.50)	(115.13)
	(2) Deferred Tax	(12.01)	(4.05)	(14.04)	(18.09)
XI	(3) *Income tax for Earlier Years*	-	-	4.35	4.35
XII	**Profit/(Loss) for the period (IX-X)**	152.72	201.98	158.23	341.80
	Earnings Per Equity Share of face value of ₹ 10/- each (Not Annualise)				
	(1) Basic (in Rs)	1.01	1.70	0.80	2.50
	(2) Diluted (in Rs)	1.01	1.70	0.80	2.50

For and behalf of Board of M/s Galaxy Medicare Limited

For Galaxy Medicare Ltd.

Dillip Kumar Das
Managing Director
DIN-00402931

Managing Director

Place: Bhubaneswar
Date :14/11/2026

A. K. SABAT & CO. Bhubaneswar Chartered Accountants

GALAXY MEDICARE LIMITED

Regd. Off: Plot No-2,Zone-D,Phase-A, Mancheswar Industrial Estate,Bhubaneswar

CIN-U242320R1992PLC003113

www.galaxy.in, Email-info@galaxy.in

Statement of Cash Flows for the Half Year ended 30th September, 2026

(Amount Rs. in Lakhs)

	Particulars	For the Half Year ended 30th September, 2026	For the Year ended 31st March,2026
		(Unaudited)	(Audited)
A.	**Cash Flow From Operating Activities**		
	Net Profit Before Taxation and Extraordinary items	218.04	470.68
	Adjustments for Non-Cash Items :		
Add:	Depreciation	39.78	55.44
	Interest Expenses	16.03	27.69
	Provision for doutful EMD	-	-
	Provision for Doubtful Debt	-	0.09
	Loss on sale of Assets	-	6.47
	Bad debts written off	-	-
	Loss on sale of Investement	0.06	4.64
	Interest Received on Loan	(6.27)	(11.28)
	Interest on Fixed Deposits with Banks	(64.69)	(39.26)
	Interest on Other Deposits	0.06	(0.38)
	Profit on sale of Investement	-	-
	Dividend Income	(0.04)	(0.21)
	Operating Profit before Working Capital changes:	**202.97**	**513.89**
	Changes in :		
	Trade Receivables	123.65	(72.20)
	Inventories	(285.29)	(69.61)
	Short term loans and advances (Asset)	50.63	(19.75)
	Other current liabilities	(2.12)	11.77
	Trade payables	130.55	120.62
	Other current assets	(101.70)	(196.55)
	Changes in long term provisions	-	0.74
	Short term provisions	-	(1.34)
	Cash Used in Operations	118.69	287.57
	Income Taxes paid	(53.30)	(110.78)
	Net Cash flow from Operating Activities	**65.38**	**176.78**
B.	**Cash Flow from Investing Activities**		
	Proceeds from sale of Fixed Assets/Investment	3.79	3.98
	Purchase of Fixed Assets	(40.20)	(160.42)
	(Increase)/Decrease in long term loans and advances	(7.11)	(1.94)
	Interest Income	70.90	50.92
	Investment in Fixed Deposits	(60.27)	(1,278.30)
	Investment in shares	0.06	(4.65)
	Dividend Income	0.04	0.21
	Net Cash flow from Investing Activities	**(32.79)**	**(1,390.20)**
C.	**Cash Flow from Financing Activities**		
	Interest Paid	(16.03)	(27.69)
	Cash proceeds from issuing shares		1,418.74
	Changes in long term Borrowings	(0.67)	30.22
	Changes in Short term borrowings	(21.19)	(70.84)
	Changes in other long term Liabilities	-	0.30
	Dividends Paid	(0.00)	(142.08)
	Net Cash flow from Financing Activities	**(37.90)**	**1,208.65**
	Net increase in Cash and Cash Equivalents	(5.29)	(4.77)
	Cash and Cash Equivalents at the beginning of the period	8.50	13.27
	Cash and Cash Equivalents at the end of the period	**3.21**	**8.50**
	Details of Cash and Cash Equivalents at the end of the period:		
	-Cash on Hand	0.21	0.05
	-Balance in Current Accounts held with Banks	3.00	8.45
	Total cash and cash equivalents	**3.21**	**8.50**

The Statement of Cash Flow has been prepared under the Indirect Method as set out in Accounting Standard 3 'Cash Flow Statements'

For and behalf of Board of M/s Galaxy Medicare Limited

For Galaxy Medicare Ltd.

Managing Director

Dillip Kumar Das
Managing Director
DIN-00402931

Place: Bhubaneswar
Date :14/11/2026

A. K. SABAT & CO. * Bhubaneswar * Chartered Accountants

GALAXY MEDICARE LIMITED

Regd. Off: Plot No-2,Zone-D,Phase-A, Mancheswar Industrial Estate,Bhubaneswar

CIN-U242320R1992PLC003113

Notes to the Financial Results for the half year ended 30th September, 2026

1 The Financial Results are prepared in accordance with Accounting Standard prescribed under Section 133 of the Companies Act 2023 read with Companies (Accounting Standards) Rules,2021 and other recognized accounting practice and policies, as applicable.

2 Companies whose shares are listed on SME platform of any exchange are exempt from compulsory adoption of IND AS and hence the Company has prepared the Financial Results as per Indian GAAP specified under Section 133 of the Companies Act, 2013, read with Companies (Accounting Standards) Rules,2021 as amended.

3 The above Financials Results of M/s Galaxy Medicare Limited (the Company) for the half year ended 30th September 2026 were reviewed and recommended by the Audit Committee and were approved by the Board of Directors in their meetings held on 14th November, 2026

4 The Statutory Auditors have carried out limited review of the Unaudited Financial Results for the half year ended September 30,2025 as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

5 The Company is operating under single segment; hence segment reporting is not applicable to the Company.

6 On 17.09.2025, 3308000 number of equity shares (excluding OFS of 824000 no of shares of Promotor) of ₹10 each were issued through IPO at a premium of ₹44 per share (total issue price ₹54 per share) aggregating to ₹ 3,30,80,000 towards face value and ₹14,55,52,000 credited to Securities Premium Account.

7 The Company has paid ₹ 50 lakh as advance to the Book Running Lead Manager (BRLM) appointed for the IPO before receipt of IPO proceeds but the same has not been adjusted by the BRLM while recovering its IPO fees from Escrow Collection Account.The amount is treated as advance recoverable and shown under "Short Term Loan and Advances".

8 Based on the recommendation of the Board, the shareholders of the Company have approved final dividend of paid a final dividend of ₹ 0.35- per equity share (3.5% on face value of ₹ 10/- each) amounting ₹ 53.10 lakh for the financial 2025-26 at 34th Annual General Meeting held on 28th September,2026 and the same was paid on 17th October,2026.

9 The previous periods' figures have been re-grouped / re-arranged wherever necessary to make it comparable with the current period.The figures of half year ended 31st March, 2026 are the balancing figures of Audited figures of full year ended 31st March ,2026 and unaudited figures of 30th September, 2025.

For and behalf of Board of M/s Galaxy Medicare Limited

For Galaxy Medicare Ltd.

Managing Director

Dillip Kumar Das
Managing Director
DIN-00402931

A. K. SABAT & CO. Bhubaneswar Chartered Accountants

Place: Bhubaneswar
Date : 14/11/2026

GALAXY MEDICARE LIMITED

Plot No.-2, Zone-D, Phase-A, Mancheswar Industrial Estate
Bhubaneswar - 751 010, Odisha, INDIA
Tel. : +91-7064810000
E-mail : info@galaxy.in
Web : http://www.galaxy.in
CIN : U24232OR1992PLC003113
GSTIN : 21AAACD7880L1ZI

An ISO 9001:2015 CERTIFIED COMPANY
Reg. No. 99 100 11576

LL-C Certification
ISO 13485:2016

November. 14, 2026

To,
National Stock Exchange of India Limited
Exchange plaza,
Bandra-Kurla Complex,
Bandra (E),
Mumbai – 400051.
SYMBOL: GML

Sub. : Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations)

Pursuant to Regulation 32 of SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer ("IPO") of the Company during the Half Year ended September 30, 2026, as mentioned in the object of the Prospectus. Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on November. 14, 2026.

This is for your information and records please.

Thanking You,

Yours Faithfully,
For Galaxy Medicare Limited
For Galaxy Medicare Ltd.

Managing Director

Dillip Kumar Das

Managing Director
DIN: 00402931

A.K. SABAT & CO.
CHARTERED ACCOUNTANTS

Plot No. : A / 348, Saheed Nagar,
Bhubaneswar - 751007, Odisha
Phone : 0674-2548264, 2549383
E-mail : aksabatco@gmail.com

To

The Board of Directors
Polt No-2, Zone-D, Phase-A,
Mancheswar Industrial Estate,
Bhubaneswar – 751010

Certificate on utilisation of the share issue proceeds by Statutory Auditors as per requirements of NSE circular no. NSE/CML/2024/23 dated 5 September 2024 and pursuant to Regulation 262 of SEBI (Issue of Capital and Disclosure Requirements) Regulations,2018.

This certificate is issued in accordance with the terms of engagement letter dated 05/10/2026 between A.K. Sabat & Co. ("we" or "us") and Galaxy Medicare Limited ("the Company").

The Company is required to submit the enclosed statement containing details of manner of the utilization of funds including funds utilized for purposes other than those stated in the offer document for the initial public issue ("the Statement") duly certified by the Statutory Auditors to the National Stock Exchange of India ('NSE') pursuant to the requirement of circular no. NSE/CML/2024/23 dated 5 September ,2024 ('NSE Circular') and pursuant to Regulation 262 of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018. The Management has requested us, the Statutory Auditors of the Company, to issue certificate on the information included in the Statement. The aforesaid Statement is initialled by us for identification purpose only.

Management's Responsibility

The Management of the Company is responsible for the preparation of the statement from the unaudited reviewed books of accounts, relevant documents and other records maintained by them. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation, that are reasonable to the circumstances.

The Management is responsible for ensuring that the Company complies with the requirements of the circulars issued by NSE, Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and for providing all relevant information to the NSE.

Auditor's Responsibility

Pursuant to the requirements stated in para 2 above, it is our responsibility to provide reasonable assurance in the form of conclusion as to whether or not the particulars as reported in the Statement have been accurately extracted from the un-audited reviewed

A.K. SABAT & CO. Bhubaneswar Chartered Accountants

Books of Accounts and other relevant records maintained by the Company for the half year ended 30th September, 2026 as provided to us and based on representations of the Management of the Company.

We have reviewed the Financial Statements of the Company for the year half year ended 30th September, 2026 on which we have issued an unmodified review report dated 14th November , 2026.

We have conducted our examination of the statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the Institute of Chartered Accountants of India. The guidance note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.

We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.

Conclusion

Based on the procedures performed and according to the information and explanations provided to us by the Management of the Company, nothing has come to our attention that causes us to believe that the Statement mentioned in "Annexure A" is not based on the information extracted from the Prospectus to public issue, Bank Statements, Invoices received from Vendors and other related records and information provided by the Company.

Restriction on use

This report is provided to the Board of Directors of the Company solely for the purpose of enabling it to comply with its obligations under the NSE circular and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For A. K. SABAT AND CO.
Chartered Accountants
Firm Reg No: 321012E



(CA B.R. Mohanty)
Partner
Mem. No: 057266
UDIN : 26057266OVGZIY7168
Place: BHUBANESWAR
Date: 14.11.2026

Annexure-A

STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED

Name of listed entity	GALAXY MEDICARE LIMITED
Mode of Fund Raising	Initial Public Offer
Date of Raising Funds	17/09/2025 (Date of Allotment)
Amount Raised	Fresh Issue of ₹1786.32 Lakhs
Report filed for Half Year ended	September 30, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Unitholders	Not Applicable
If Yes, Date of Unitholders Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments
Objects for which funds have been raised and here there has been a deviation, in the following table	No Deviation

Original Object	**Original Allocation** *(₹ in Lakh)*	**Funds Utilised** *(₹ in Lakh)*	**Unutilised Amount** *(₹ in Lakh)*	**Remarks if any**
Issue related expenses	178.64	178.64	-	-
Meeting our Working Capital requirements**	893.96	51.20**	842.76	-
Funding Capital Expenditure requirement towards purchase of machinery for our existing manufacturing facility at Bhubaneswar, odisha	488.76	56.44	432.32	-
General Corporate Expense	224.96	224.96	-	-
Total	**1786.32**	**511.24**	1275.08	

A.K. SABAT & CO. * Bhubaneswar * Chartered Accountants

****Detailed Utilization of IPO Proceeds for the Purpose of Working Capital as on 30/09/2026**

(Rs. In Lakhs)

SL. No	Particular	As disclosed in Prospectus	Utilization Upto 30th September 2026
I	**CURRENT ASSETS**		
	Inventories	664.32	51.20
	Trade Receivables	878.14	-
	Short Term Loan & Advances	205.67	-
	Other Current Assets	73.09	-
	TOTAL (A)	**1821.22**	**51.20**
II	**CURRENT LIABILITIES**		
	Trade Payables	136.77	-
	Other Current Liabilities	99.73	-
	Short Term Provisions	181.93	-
	TOTAL (B)	**418.43**	-
	Net Working Capital (A) - (B)	**1402.79**	-
	Funding Pattern		
	Borrowings from Bank	377.09	-
	Internal Sources	131.74	-
	Working Capital Gap to be Funded by IPO	**893.96**	**51.20**
III	**Working Capital (Utilized)**		**51.20**

1. As per the Object disclosed in the Offer Document, Rs 893.96 Lakhs is Allocated for Working Capital, out of which Rs 51.20 Lakhs has been Utilized as on 30th September 2026 as stated above.

2. Based on the Information, Explanations given to us and as per examination of Documents provided to us, the Utilization of IPO Proceeds is in Compliance with the prescribed purposes as mentioned in the Offer Document.
   This Statement is being issued in Compliance with the Regulatory Requirements and under the Applicable Laws.

For A. K. SABAT AND CO.
Chartered Accountants
Firm Reg No: 321012E



(CA B.R. Mohanty)
Partner
Mem. No: 057266
UDIN :26057266OVGZIY7168
Place: BHUBANESWAR
Date: 14.11.2026

GALAXY MEDICARE LIMITED

Plot No.-2, Zone-D, Phase-A, Mancheswar Industrial Estate
Bhubaneswar - 751 010, Odisha, INDIA
Tel. : +91-7064810000
E-mail : info@galaxy.in
Web : http://www.galaxy.in
CIN : U24232OR1992PLC003113
GSTIN : 21AAACD7880L1ZI

An ISO 9001:2015 CERTIFIED COMPANY
Reg. No. 99 100 11576

ISO 13485:2016

Date: 14th November 2026

To,
The Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai - 400051

NSE SYMBOL: GML	ISIN: INE09A801015

Sub: Disclosure Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Unmodified Audit Opinion.

Dear Sir/Madam,

In Compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby declare that the Statutory Auditors of the Company, M/s A. K. Sabat & Co, Chartered Accountants, (Firm Registration No. 321012E) have issued an Limited Review Report with an Unmodified Opinion on the Unaudited Financial Results (Standalone) of the Company for the Half Year Ended on 30th September 2026.

You are requested to kindly take the above information on record.

Thanking You.

Yours Faithfully,

For Galaxy Medicare Limited
For Galaxy Medicare Ltd.

Managing Director

Dillip Kumar Das
(Managing Director)
DIN: 00402931

GALAXY MEDICARE LIMITED

Plot No.-2, Zone-D, Phase-A, Mancheswar Industrial Estate
Bhubaneswar - 751 010, Odisha, INDIA
Tel. : +91-7064810000
E-mail : info@galaxy.in
Web : http://www.galaxy.in
CIN : U24232OR1992PLC003113
GSTIN : 21AAACD7880L1ZI

An ISO 9001:2015 CERTIFIED COMPANY
Reg. No. 99 100 11576

ISO 13485:2016

Date: 14th November 2026

To,
The Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai - 400051

NSE SYMBOL: GML	ISIN: INE09A801015

Sub: Disclosure Pursuant to Regulation 33 (2) (a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In Compliance with Regulation 33 (2) (a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm, declare and certify that the Unaudited Financial Results (Standalone) for the Half Year Ended on 30th September 2026 do not contain any False or Misleading Statement or Figures and do not omit any material fact which may make the Statements or Figures contained therein Misleading.

You are requested to kindly take the above information on record.

Thanking You.

Yours Faithfully,

For Galaxy Medicare Limited
For Galaxy Medicare Ltd.

Managing Director

Dillip Kumar Das
(Managing Director)
DIN: 00402931